Business
Satellos Bioscience Announces Appointment of J. Robert Hall as Vice-President, Finance and Administration
Toronto, Ontario--(Newsfile Corp. - September 17, 2021) - Satellos Bioscience Inc. (TSXV: MSCL...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience Announces Appointment of J. Robert Hall as Vice-President, Finance and AdministrationToronto, Ontario--(Newsfile Corp. - September 17, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) (Satellos\" or the \"Company\"), a regenerative medicine company focused on the treatment of Duchenne muscular dystrophy and other degenerative or muscle wasting disorders, is pleased to announce that the Company's board of directors has appointed J. Robert Hall, CFA as Vice-President, Finance & Administration.Mr. Hall has been with Satellos since January of 2020, serving in various finance and administration related roles. In his new role he will continue to support both the CEO and CFO of Satellos. Rob brings thirty years of progressive financial management experience in the Canadian biotechnology industry, and has worked in biomanufacturing, research, venture capital and debt financing, and with start-up firms. Rob holds BSc (Biochemistry) and MBA degrees and is a Chartered Financial Analyst charter holder.\"We are very pleased to appoint Mr. Hall as an officer of Satellos,\" said Frank Gleeson, the Company's CEO. \"Rob's deep background in financial management in our sector is an invaluable asset as we position for rapid growth and value creation. He provides Satellos with significant analytical and valuation capability which will be vital going forward as we assess business opportunities and pursue future financing options.\"About SatellosSatellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos' lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery pla...